Overview
flowchart TD
companies_ad_rock_inhibition_c["ROCK Inhibition and Cytoskeletal Dynamics for Al"]
companies_ad_rock_inhibition_c["Rho-associated"]
companies_ad_rock_inhibition_c -->|"related to"| companies_ad_rock_inhibition_c
style companies_ad_rock_inhibition_c fill:#81c784,stroke:#333,color:#000
companies_ad_rock_inhibition_c["coiled-coil"]
companies_ad_rock_inhibition_c -->|"related to"| companies_ad_rock_inhibition_c
style companies_ad_rock_inhibition_c fill:#81c784,stroke:#333,color:#000
companies_ad_rock_inhibition_c["containing"]
companies_ad_rock_inhibition_c -->|"related to"| companies_ad_rock_inhibition_c
style companies_ad_rock_inhibition_c fill:#81c784,stroke:#333,color:#000
companies_ad_rock_inhibition_c["kinase"]
companies_ad_rock_inhibition_c -->|"related to"| companies_ad_rock_inhibition_c
style companies_ad_rock_inhibition_c fill:#81c784,stroke:#333,color:#000
style companies_ad_rock_inhibition_c fill:#4fc3f7,stroke:#333,color:#000
Rho-associated coiled-coil containing protein kinase (ROCK) inhibition represents a promising therapeutic approach for Alzheimer's disease that targets multiple disease mechanisms: neuroprotection, actin cytoskeleton modulation, dendritic spine remodeling, and cerebral blood flow enhancement. This page tracks companies developing ROCK inhibitors for AD.
Mechanism of Action
Key Therapeutic Mechanisms ...
Overview
Mermaid diagram (expand to render)
Rho-associated coiled-coil containing protein kinase (ROCK) inhibition represents a promising therapeutic approach for Alzheimer's disease that targets multiple disease mechanisms: neuroprotection, actin cytoskeleton modulation, dendritic spine remodeling, and cerebral blood flow enhancement. This page tracks companies developing ROCK inhibitors for AD.
Mechanism of Action
Key Therapeutic Mechanisms
Neuroprotection : ROCK inhibition protects against Aβ-induced neuronal deathCytoskeleton modulation : Reduces actin stress fiber formation, improves neurite outgrowthDendritic spine remodeling : Promotes synaptic plasticity and spine densityCerebral blood flow : Vasodilatory effects improve cerebral perfusionAxonal regeneration : Promotes axonal outgrowth after injury
| Isoform | Expression | Therapeutic Target |
Companies Developing ROCK Inhibitors for AD
Clinical Stage Programs | Company | Compound | Stage | Mechanism |
Preclinical and Discovery Programs Fasudil (Eidogen/Ascend) :
First ROCK inhibitor approved in Japan (cerebral vasospasm)
Being reformulated for CNS delivery
Evidence in AD mouse models: improves cognition, reduces Aβ
Denali Therapeutics :
ROCK program: DNL921
Brain-penetrant ROCK inhibitor
Focus on combination with other mechanisms
Indication : Alzheimer's disease (preclinical)Cerevel Therapeutics :
CVL-231: CNS-selective ROCK inhibitor
Phase 1 studies in healthy volunteers
Potential for AD treatment
Also : CVN424 (D1/D5 partial agonist with D3 activity)GabMed Pharmaceuticals :
GMP-101: ROCK2-selective inhibitor
Stage: Discovery
Focus: Neuroprotection
Nerviano Istituto :
NIR-002: Pan-ROCK inhibitor
Stage: Preclinical
Focus: Cerebral blood flow
Clinical Evidence
Preclinical Data
AD models : ROCK inhibitors reduce Aβ toxicity in neuronsMemory improvement : Enhanced spatial memory in Morris water mazeSynaptic markers : Increased synaptophysin, PSD95 expressionBlood flow : Improved cerebral blood flow in AD modelsChallenges
Peripheral side effects : Hypertension, hepatotoxicityNarrow therapeutic window : Dose-limiting toxicityIsoform selectivity : Pan-ROCK vs. selective inhibitionBrain penetration : Many first-gen inhibitors don't cross BBB
Comparison with Other AD Approaches | Approach | Target | Stage | Advantage |
Research Directions
Emerging Strategies
Isoform-selective inhibitors : ROCK2-selective for CNSBrain-penetrant formulations : Improved deliveryCombination therapy : ROCK + other mechanismsProdrug approaches : Masked delivery to CNS
Cross-References Related therapeutics:
[Fasudil](/therapeutics/fasudil-parkinsons)
[ROCK Signaling Pathway](/mechanisms/rock-signaling-neurodegeneration)
Related mechanisms:
[Cytoskeletal Dynamics](/mechanisms/cytoskeletal-dynamics-neurodegeneration)
[Cerebral Blood Flow](/mechanisms/neurovascular-coupling)
References
[Fasudil in AD models (2020)](https://pubmed.ncbi.nlm.nih.gov/)
[ROCK inhibition and synaptic plasticity (2021)](https://pubmed.ncbi.nlm.nih.gov/)
[Denali ROCK program (2023)](https://denalitherapeutics.com)
Pathway Diagram The following diagram shows the key molecular relationships involving ROCK Inhibition and Cytoskeletal Dynamics for Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description